Competition regulators are clamping down on pharmaceutical companies trying to block the sale of cheap, generic drugs, Science Business reports.
According to the website, last month the Commission launched an inquiry challenging suspected collusion between pharmaceutical companies Johnson & Johnson and Novartis, who were allegedly attempting to prevent the sale of generic, or non-patented copies, of medicines.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.